MDxHealth（MDXH）株式概要MDxHealth SAは、商業段階の精密診断企業であり、米国、欧州、および国際的に泌尿器科ソリューションを提供している。 詳細MDXH ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より93.9%で取引されている 同業他社や業界と比較して、良好な取引価格 リスク分析マイナスの株主資本 現在は利益が出ておらず、今後3年間で利益が出る見込みはない US市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( $42M )すべてのリスクチェックを見るMDXH Community Fair Values Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN88.6% undervaluedAnalystConsensusTarget•4mo agoUrology Test Integration And Expanded Sales Force Will Support Future Earnings Turnaround1604AN91.1% undervaluedAnalystHighTarget•5mo agoLiquid Diagnostics And Expanding Lab Footprint Will Drive Strong Long Term Outcomes1300AN81.0% undervaluedAnalystLowTarget•4mo agoExoDx Integration Risks May Strain Urology Diagnostics While Long-Term Tissue Testing Prospects Improve903Top Analyst NarrativesAN88.6% undervaluedAnalystConsensusTarget•4mo agoUrology Test Integration And Expanded Sales Force Will Support Future Earnings Turnaround1604AN91.1% undervaluedAnalystHighTarget•5mo agoLiquid Diagnostics And Expanding Lab Footprint Will Drive Strong Long Term Outcomes1300AN81.0% undervaluedAnalystLowTarget•4mo agoExoDx Integration Risks May Strain Urology Diagnostics While Long-Term Tissue Testing Prospects Improve903View all narrativesMDxHealth SA 競合他社CervoMedSymbol: NasdaqCM:CRVOMarket cap: US$28.6mPlus TherapeuticsSymbol: NasdaqCM:PSTVMarket cap: US$47.3mImmuCellSymbol: NasdaqCM:ICCCMarket cap: US$90.6mBioXcel TherapeuticsSymbol: NasdaqCM:BTAIMarket cap: US$30.9m価格と性能株価の高値、安値、推移の概要MDxHealth過去の株価現在の株価US$0.8052週高値US$5.3352週安値US$0.68ベータ-510468.061ヶ月の変化-64.91%3ヶ月変化-77.96%1年変化-60.78%3年間の変化n/a5年間の変化-95.51%IPOからの変化-99.09%最新ニュースMajor Estimate Revision • May 20Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$137.3m to US$115.2m. Forecast losses increased from -US$0.444 to -US$0.678 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$7.40 to US$3.90. Share price fell 55% to US$0.84 over the past week.Reported Earnings • May 14Full year 2025 earnings released: US$0.67 loss per share (vs US$1.16 loss in FY 2024)Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.Breakeven Date Change • May 14No longer forecast to breakevenThe 6 analysts covering MDxHealth no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.97m in 2028. New consensus forecast suggests the company will make a loss of US$11.3m in 2028.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$34m Forecast net loss in 3 years: US$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years).New Risk • May 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Market cap is less than US$100m (US$96.1m market cap).Reported Earnings • Apr 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.最新情報をもっと見るRecent updatesMajor Estimate Revision • May 20Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$137.3m to US$115.2m. Forecast losses increased from -US$0.444 to -US$0.678 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$7.40 to US$3.90. Share price fell 55% to US$0.84 over the past week.Reported Earnings • May 14Full year 2025 earnings released: US$0.67 loss per share (vs US$1.16 loss in FY 2024)Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.Breakeven Date Change • May 14No longer forecast to breakevenThe 6 analysts covering MDxHealth no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.97m in 2028. New consensus forecast suggests the company will make a loss of US$11.3m in 2028.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$34m Forecast net loss in 3 years: US$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years).New Risk • May 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Market cap is less than US$100m (US$96.1m market cap).Reported Earnings • Apr 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.お知らせ • Mar 17MDxHealth SA Highlights Data from Oxford’s Prompt Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings At EAU 2026Mdxhealth SA announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London. The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford, highlighted how the GPS mdx assay identified patients with biologically indolent prostate cancer despite adverse clinical risk factors. The findings demonstrate how GPS mdx insights help personalize treatment decisions by identifying patients who may safely benefit from treatment de-escalation. The GPS-ProMPT study evaluated 409 patients with localized or locally advanced prostate cancer with a median follow-up of at least six years. Patients in the cohort were managed with active surveillance, radical prostatectomy, or radiotherapy, enabling investigators to assess the predictive performance of the GPS mdx test across multiple treatment pathways. The GPS mdx test successfully stratified the risk of treatment failure across treatment cohorts. Six-year freedom-from-failure outcomes were excellent in these discordant groups, including 92% in Active Surveillance patients and up to 100% among patients treated with surgery or radiotherapy, outcomes that are comparable to concordant low-risk patients.Major Estimate Revision • Mar 06Consensus EPS estimates fall by 46%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.28 to -US$0.41 per share. Revenue forecast unchanged at US$136.6m. Biotechs industry in the US expected to see average net income decline 8.6% next year. Consensus price target of US$7.40 unchanged from last update. Share price fell 3.8% to US$3.27 over the past week.Breakeven Date Change • Mar 02Forecast breakeven date pushed back to 2028The 6 analysts covering MDxHealth previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 58% per year to 2027. The company is expected to make a profit of US$3.70m in 2028. Average annual earnings growth of 79% is required to achieve expected profit on schedule.New Risk • Feb 27New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$31m Forecast net loss in 2 years: US$2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.3m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$2.0m net loss in 2 years).お知らせ • Feb 27MDxHealth SA Maintains Earnings Guidance for the Year 2026MDxHealth SA maintained earnings guidance for the year 2026. For the year, the company expects revenue guidance of $137 million - $140 million.新しいナラティブ • Feb 22MDxHealth SA (MDXH) Precision Diagnostics: Bridging the Gap to ProfitabilityMDxHealth (MDXH) is currently one of the most talked-about names in the precision diagnostics space, trading at $3.63 as of late February 2026. Headquartered in Belgium with significant U.S. operations, the company has successfully transitioned into a commercial-stage powerhouse focused on urologic cancers.お知らせ • Jan 12+ 3 more updatesMDxHealth SA to Report Fiscal Year 2025 Results on Feb 26, 2026MDxHealth SA announced that they will report fiscal year 2025 results on Feb 26, 2026分析記事 • Dec 02MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive EnoughMDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...Breakeven Date Change • Nov 28Forecast to breakeven in 2027The 6 analysts covering MDxHealth expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2026. The company is expected to make a profit of US$2.35m in 2027. Average annual earnings growth of 81% is required to achieve expected profit on schedule.お知らせ • Nov 13MDxHealth SA Provides Earnings Guidance for the Fourth Quarter of 2025 and Reaffirms Earnings Guidance for the Full Year of 2025MDxHealth SA provided earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects fourth quarter revenue growth to meet or exceed 20%. Despite the elimination of expected Germline revenue contribution in Third Quarter and Q4, the company remain confident in reaffirming full-year guidance of $108 million to $110 million and expect full year revenue growth to meet or exceed 20%.お知らせ • Sep 16MDxHealth SA (NasdaqCM:MDXH) acquired Business of Exosome Diagnostics, Inc.MDxHealth SA (NasdaqCM:MDXH) signed a definitive agreement to acquire Business of Exosome Diagnostics, Inc. for $15 million on August 5, 2025. Total consideration for the acquisition is $15 million, with $5 million in stock to be paid at closing and $2.5 million annually over the following 4 years with 50% payable in cash and 50% payable in cash or stock. The transaction is subject to customary closing conditions and is expected to close in September. XMS Capital Partners acted as financial advisor and K&L Gates acted as legal advisor to MDxHealth for this acquisition, Baker McKenzie served as legal advisor for Belgian corporate matters. MDxHealth SA (NasdaqCM:MDXH) completed the acquisition of Business of Exosome Diagnostics, Inc. on September 15, 2025.お知らせ • Aug 06Mdxhealth SA Reaffirms Revenue Guidance for 2025Mdxhealth SA reaffirmed revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million.お知らせ • Jul 04+ 1 more updateMDxHealth SA Appoints Michael Holder to Board of DirectorsMDxHealth SA announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $250M private investment company and most recently served as CEO of Sensable Health, an AI-powered wellness program, while also holding board positions at Cytek Biosciences Inc. (where he is Chair of the Audit Committee), and Keyron Medical Ltd. Mr. Holder received an MBA from the Wharton School, a BS in Business from the University of North Carolina, and previously earned his Certified Public Accountant licensure.お知らせ • May 15Mdxhealth Sa Reiterates Revenue Guidance for 2025Mdxhealth Sa reiterated revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million.お知らせ • Feb 27MDxHealth SA Reaffirms Earnings Guidance for the Year 2025MDxHealth SA reaffirms earnings guidance for the year 2025. The Company is maintaining its previously issued 2025 revenue guidance of $108 million to $110 million.お知らせ • Jan 13+ 4 more updatesMDxHealth SA to Report Q3, 2025 Results on Nov 12, 2025MDxHealth SA announced that they will report Q3, 2025 results on Nov 12, 2025お知らせ • Nov 07+ 1 more updateMDxHealth SA Provides Revenue Guidance for the Year 2025MDxHealth SA provided revenue guidance for the year 2025. The company expects 2025 revenue to meet or exceed its long-term objective of 20% sustainable growth.お知らせ • Sep 26MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million. Security Name: Ordinary Shares Security Type: Common Stockお知らせ • Jul 08+ 1 more updateMdxhealth SA Raises Earnings Guidance for the Year 2024MDxHealth SA raised earnings guidance for the year 2024. Based on our visibility to sustainable growth, company is taking revenue guidance up from $83-85 million to $85-87 million, representing 23% year-over-year revenue growth at the midpoint of guidance.お知らせ • May 03MDxHealth SA Revises Earnings Guidance for the Year 2024MDxHealth SA revised earnings guidance for the year 2024. For the period, the company is increasing 2024 revenue guidance to $83 million to 85 million from the previous $79 million to 81 million.お知らせ • May 01MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 13Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer OfferingMdxhealth SA announced the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.ermline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients. Prostate cancer remains a leading cause of cancer-related death among men, with an estimated 288,300 new diagnoses and 34,700 deaths annually. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of neurological cancers and other urologic diseases.お知らせ • Mar 07MDxHealth SA Maintains Earnings Guidance for the Year 2024MDxHealth SA maintained earnings guidance for the year 2024. For the year, the company is maintaining its previously issued 2024 revenue guidance of $79-81 million.お知らせ • Feb 16MDxHealth SA Announces Jan Pensaert Steps Down from its Board of DirectorsMDxHealth SA announced that Jan Pensaert has stepped down from the Board of Directors. His resignation was effective as of February 15, 2024. Mr. Pensaert’s resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.お知らせ • Jan 09MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024MDxHealth SA provided earnings guidance for the fourth quarter and full year 2023 and year 2024. For the quarter, Company expects revenue of approximately $19.4 million. For the full year 2023, Company expects revenue of approximately $70.2 million. For the year 2024, Company expects revenue $79 million to $81 million. which would represent year-over-year revenue growth of approximately 13%-15%.お知らせ • Jan 06+ 4 more updatesMDxHealth SA to Report Q1, 2024 Results on May 08, 2024MDxHealth SA announced that they will report Q1, 2024 results on May 08, 2024お知らせ • Nov 29MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023MDxHealth SA announced the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") facility (the "Mandatory ADS Exchange"), the start of the transition to a single listing on Nasdaq, and details on the process for repositioning of the Company's shares from the Euronext Brussels trading system to the Nasdaq trading system. The Company announced on October 2, 2023, that its board of directors had determined that it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company's securities on one exchange in the United States. This transaction involves (1) a share consolidation with respect to all outstanding Company shares by means of a 1-for-10 reverse stock split, which was completed on November 13, 2023 (the "Share Consolidation"), after which ten former Company shares are represented by one new Company share (each new Company share, a "Share"), and each ADS represents one new Share, (2) listing the Shares on Nasdaq, (3) the Mandatory ADS Exchange, (4) a repositioning of the Shares from the Euronext Brussels trading system to the Nasdaq trading system, and (5) following a transition period of at least three weeks after the Mandatory ADS Exchange, the de-listing of the Shares from listing and trading on Euronext Brussels. Following the completion of the Share Consolidation on November 13, 2023, the Company completed the Mandatory ADS Exchange, effective November 27, 2023. As a result of the Mandatory ADS Exchange, ADS holders received Shares that are listed on Nasdaq in exchange for their ADSs on the basis of a ratio of one ADS for one Share, the ADS program will be terminated and the ADSs will cease to be listed and traded on Nasdaq. Effective as of the opening of trading on Nasdaq today, the Shares will be admitted to listing and trading on Nasdaq. During a transition period ending December 15, 2023, the Shares will be listed on both Euronext Brussels and Nasdaq. In view of the foregoing, effective as of close of trading on Euronext Brussels on December 15, 2023, the Shares will no longer be listed and traded on Euronext Brussels. As of that moment on, the Shares will only be listed and traded on Nasdaq.お知らせ • Nov 11MDxHealth SA Provides Earnings Guidance for the Year 2023MDxHealth SA provided earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million.お知らせ • Nov 10MDxHealth SA Revises Earnings Guidance for the Year 2023MDxHealth SA revised earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million.お知らせ • Oct 05MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023MDxHealth SA announced that they will report Q3, 2023 results at 5:40 PM, Central European Standard Time on Oct 09, 2023お知らせ • Aug 24MDxHealth SA Reaffirms Revenue Guidance for the Year 2023MDxHealth SA announced that the company reaffirms full year 2023 revenue guidance of $65 million - $70 million.お知らせ • Jan 10+ 1 more updateMDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023MDxHealth SA announced that they will report first half, 2023 results on Aug 23, 2023株主還元MDXHUS BiotechsUS 市場7D-10.4%1.2%1.0%1Y-60.8%34.9%28.7%株主還元を見る業界別リターン: MDXH過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: MDXHは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is MDXH's price volatile compared to industry and market?MDXH volatilityMDXH Average Weekly Movement15.6%Biotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: MDXHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: MDXHの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003364Mike McGarritymdxhealth.com商業段階の精密診断企業であるMDxHealth SAは、米国、欧州、および国際的に泌尿器科ソリューションを提供している。同社の検査ソリューションには、過去に生検された陰性組織から潜伏性前立腺がんを検出するためのエピジェネティック検査を検証するConfirm mdx for prostate cancer tissue test、臨床的に前立腺がんに罹患するリスクを評価する非侵襲的尿検査ExoD、患者の感染症に対して有効な抗生物質の選択肢を個別に特定するResolve mdx for urinary tract infectionなどがある。また、複雑な前立腺癌の診断と治療を行う医師と患者に対して、個別化されたゲノムの知見を提供するGenomic prostate scoreを提供している。同社は、直接営業担当者、戦略的アカウントマネージャー、地域営業マネージャーで構成される泌尿器科営業チームを通じて製品を販売している。同社はGenomic Prostate Score (GPS)検査を共同で開始している。同社は以前OncoMethylome Sciences SAとして知られていたが、2010年10月にMDxHealth SAに社名を変更した。MDxHealth SAは2003年に設立され、ベルギーのHerstalに本社を置いている。もっと見るMDxHealth SA 基礎のまとめMDxHealth の収益と売上を時価総額と比較するとどうか。MDXH 基礎統計学時価総額US$42.43m収益（TTM）-US$33.18m売上高(TTM)US$110.97m0.4xP/Sレシオ-1.2xPER（株価収益率MDXH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MDXH 損益計算書（TTM）収益US$110.97m売上原価US$40.23m売上総利益US$70.74mその他の費用US$103.92m収益-US$33.18m直近の収益報告Mar 31, 2026次回決算日Aug 13, 2026一株当たり利益（EPS）-0.65グロス・マージン63.75%純利益率-29.90%有利子負債／自己資本比率-474.3%MDXH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 09:29終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MDxHealth SA 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Michael Ruzic-GauthierBerenbergMark MassaroBTIGWilliam BonelloCraig-Hallum Capital Group LLC10 その他のアナリストを表示
Major Estimate Revision • May 20Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$137.3m to US$115.2m. Forecast losses increased from -US$0.444 to -US$0.678 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$7.40 to US$3.90. Share price fell 55% to US$0.84 over the past week.
Reported Earnings • May 14Full year 2025 earnings released: US$0.67 loss per share (vs US$1.16 loss in FY 2024)Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
Breakeven Date Change • May 14No longer forecast to breakevenThe 6 analysts covering MDxHealth no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.97m in 2028. New consensus forecast suggests the company will make a loss of US$11.3m in 2028.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$34m Forecast net loss in 3 years: US$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years).
New Risk • May 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Market cap is less than US$100m (US$96.1m market cap).
Reported Earnings • Apr 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • May 20Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$137.3m to US$115.2m. Forecast losses increased from -US$0.444 to -US$0.678 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$7.40 to US$3.90. Share price fell 55% to US$0.84 over the past week.
Reported Earnings • May 14Full year 2025 earnings released: US$0.67 loss per share (vs US$1.16 loss in FY 2024)Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
Breakeven Date Change • May 14No longer forecast to breakevenThe 6 analysts covering MDxHealth no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.97m in 2028. New consensus forecast suggests the company will make a loss of US$11.3m in 2028.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$34m Forecast net loss in 3 years: US$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years).
New Risk • May 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Market cap is less than US$100m (US$96.1m market cap).
Reported Earnings • Apr 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
お知らせ • Mar 17MDxHealth SA Highlights Data from Oxford’s Prompt Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings At EAU 2026Mdxhealth SA announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London. The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford, highlighted how the GPS mdx assay identified patients with biologically indolent prostate cancer despite adverse clinical risk factors. The findings demonstrate how GPS mdx insights help personalize treatment decisions by identifying patients who may safely benefit from treatment de-escalation. The GPS-ProMPT study evaluated 409 patients with localized or locally advanced prostate cancer with a median follow-up of at least six years. Patients in the cohort were managed with active surveillance, radical prostatectomy, or radiotherapy, enabling investigators to assess the predictive performance of the GPS mdx test across multiple treatment pathways. The GPS mdx test successfully stratified the risk of treatment failure across treatment cohorts. Six-year freedom-from-failure outcomes were excellent in these discordant groups, including 92% in Active Surveillance patients and up to 100% among patients treated with surgery or radiotherapy, outcomes that are comparable to concordant low-risk patients.
Major Estimate Revision • Mar 06Consensus EPS estimates fall by 46%The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.28 to -US$0.41 per share. Revenue forecast unchanged at US$136.6m. Biotechs industry in the US expected to see average net income decline 8.6% next year. Consensus price target of US$7.40 unchanged from last update. Share price fell 3.8% to US$3.27 over the past week.
Breakeven Date Change • Mar 02Forecast breakeven date pushed back to 2028The 6 analysts covering MDxHealth previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 58% per year to 2027. The company is expected to make a profit of US$3.70m in 2028. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
New Risk • Feb 27New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$31m Forecast net loss in 2 years: US$2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.3m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$2.0m net loss in 2 years).
お知らせ • Feb 27MDxHealth SA Maintains Earnings Guidance for the Year 2026MDxHealth SA maintained earnings guidance for the year 2026. For the year, the company expects revenue guidance of $137 million - $140 million.
新しいナラティブ • Feb 22MDxHealth SA (MDXH) Precision Diagnostics: Bridging the Gap to ProfitabilityMDxHealth (MDXH) is currently one of the most talked-about names in the precision diagnostics space, trading at $3.63 as of late February 2026. Headquartered in Belgium with significant U.S. operations, the company has successfully transitioned into a commercial-stage powerhouse focused on urologic cancers.
お知らせ • Jan 12+ 3 more updatesMDxHealth SA to Report Fiscal Year 2025 Results on Feb 26, 2026MDxHealth SA announced that they will report fiscal year 2025 results on Feb 26, 2026
分析記事 • Dec 02MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive EnoughMDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...
Breakeven Date Change • Nov 28Forecast to breakeven in 2027The 6 analysts covering MDxHealth expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2026. The company is expected to make a profit of US$2.35m in 2027. Average annual earnings growth of 81% is required to achieve expected profit on schedule.
お知らせ • Nov 13MDxHealth SA Provides Earnings Guidance for the Fourth Quarter of 2025 and Reaffirms Earnings Guidance for the Full Year of 2025MDxHealth SA provided earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects fourth quarter revenue growth to meet or exceed 20%. Despite the elimination of expected Germline revenue contribution in Third Quarter and Q4, the company remain confident in reaffirming full-year guidance of $108 million to $110 million and expect full year revenue growth to meet or exceed 20%.
お知らせ • Sep 16MDxHealth SA (NasdaqCM:MDXH) acquired Business of Exosome Diagnostics, Inc.MDxHealth SA (NasdaqCM:MDXH) signed a definitive agreement to acquire Business of Exosome Diagnostics, Inc. for $15 million on August 5, 2025. Total consideration for the acquisition is $15 million, with $5 million in stock to be paid at closing and $2.5 million annually over the following 4 years with 50% payable in cash and 50% payable in cash or stock. The transaction is subject to customary closing conditions and is expected to close in September. XMS Capital Partners acted as financial advisor and K&L Gates acted as legal advisor to MDxHealth for this acquisition, Baker McKenzie served as legal advisor for Belgian corporate matters. MDxHealth SA (NasdaqCM:MDXH) completed the acquisition of Business of Exosome Diagnostics, Inc. on September 15, 2025.
お知らせ • Aug 06Mdxhealth SA Reaffirms Revenue Guidance for 2025Mdxhealth SA reaffirmed revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million.
お知らせ • Jul 04+ 1 more updateMDxHealth SA Appoints Michael Holder to Board of DirectorsMDxHealth SA announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $250M private investment company and most recently served as CEO of Sensable Health, an AI-powered wellness program, while also holding board positions at Cytek Biosciences Inc. (where he is Chair of the Audit Committee), and Keyron Medical Ltd. Mr. Holder received an MBA from the Wharton School, a BS in Business from the University of North Carolina, and previously earned his Certified Public Accountant licensure.
お知らせ • May 15Mdxhealth Sa Reiterates Revenue Guidance for 2025Mdxhealth Sa reiterated revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million.
お知らせ • Feb 27MDxHealth SA Reaffirms Earnings Guidance for the Year 2025MDxHealth SA reaffirms earnings guidance for the year 2025. The Company is maintaining its previously issued 2025 revenue guidance of $108 million to $110 million.
お知らせ • Jan 13+ 4 more updatesMDxHealth SA to Report Q3, 2025 Results on Nov 12, 2025MDxHealth SA announced that they will report Q3, 2025 results on Nov 12, 2025
お知らせ • Nov 07+ 1 more updateMDxHealth SA Provides Revenue Guidance for the Year 2025MDxHealth SA provided revenue guidance for the year 2025. The company expects 2025 revenue to meet or exceed its long-term objective of 20% sustainable growth.
お知らせ • Sep 26MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million. Security Name: Ordinary Shares Security Type: Common Stock
お知らせ • Jul 08+ 1 more updateMdxhealth SA Raises Earnings Guidance for the Year 2024MDxHealth SA raised earnings guidance for the year 2024. Based on our visibility to sustainable growth, company is taking revenue guidance up from $83-85 million to $85-87 million, representing 23% year-over-year revenue growth at the midpoint of guidance.
お知らせ • May 03MDxHealth SA Revises Earnings Guidance for the Year 2024MDxHealth SA revised earnings guidance for the year 2024. For the period, the company is increasing 2024 revenue guidance to $83 million to 85 million from the previous $79 million to 81 million.
お知らせ • May 01MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 13Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer OfferingMdxhealth SA announced the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.ermline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients. Prostate cancer remains a leading cause of cancer-related death among men, with an estimated 288,300 new diagnoses and 34,700 deaths annually. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of neurological cancers and other urologic diseases.
お知らせ • Mar 07MDxHealth SA Maintains Earnings Guidance for the Year 2024MDxHealth SA maintained earnings guidance for the year 2024. For the year, the company is maintaining its previously issued 2024 revenue guidance of $79-81 million.
お知らせ • Feb 16MDxHealth SA Announces Jan Pensaert Steps Down from its Board of DirectorsMDxHealth SA announced that Jan Pensaert has stepped down from the Board of Directors. His resignation was effective as of February 15, 2024. Mr. Pensaert’s resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.
お知らせ • Jan 09MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024MDxHealth SA provided earnings guidance for the fourth quarter and full year 2023 and year 2024. For the quarter, Company expects revenue of approximately $19.4 million. For the full year 2023, Company expects revenue of approximately $70.2 million. For the year 2024, Company expects revenue $79 million to $81 million. which would represent year-over-year revenue growth of approximately 13%-15%.
お知らせ • Jan 06+ 4 more updatesMDxHealth SA to Report Q1, 2024 Results on May 08, 2024MDxHealth SA announced that they will report Q1, 2024 results on May 08, 2024
お知らせ • Nov 29MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023MDxHealth SA announced the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") facility (the "Mandatory ADS Exchange"), the start of the transition to a single listing on Nasdaq, and details on the process for repositioning of the Company's shares from the Euronext Brussels trading system to the Nasdaq trading system. The Company announced on October 2, 2023, that its board of directors had determined that it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company's securities on one exchange in the United States. This transaction involves (1) a share consolidation with respect to all outstanding Company shares by means of a 1-for-10 reverse stock split, which was completed on November 13, 2023 (the "Share Consolidation"), after which ten former Company shares are represented by one new Company share (each new Company share, a "Share"), and each ADS represents one new Share, (2) listing the Shares on Nasdaq, (3) the Mandatory ADS Exchange, (4) a repositioning of the Shares from the Euronext Brussels trading system to the Nasdaq trading system, and (5) following a transition period of at least three weeks after the Mandatory ADS Exchange, the de-listing of the Shares from listing and trading on Euronext Brussels. Following the completion of the Share Consolidation on November 13, 2023, the Company completed the Mandatory ADS Exchange, effective November 27, 2023. As a result of the Mandatory ADS Exchange, ADS holders received Shares that are listed on Nasdaq in exchange for their ADSs on the basis of a ratio of one ADS for one Share, the ADS program will be terminated and the ADSs will cease to be listed and traded on Nasdaq. Effective as of the opening of trading on Nasdaq today, the Shares will be admitted to listing and trading on Nasdaq. During a transition period ending December 15, 2023, the Shares will be listed on both Euronext Brussels and Nasdaq. In view of the foregoing, effective as of close of trading on Euronext Brussels on December 15, 2023, the Shares will no longer be listed and traded on Euronext Brussels. As of that moment on, the Shares will only be listed and traded on Nasdaq.
お知らせ • Nov 11MDxHealth SA Provides Earnings Guidance for the Year 2023MDxHealth SA provided earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million.
お知らせ • Nov 10MDxHealth SA Revises Earnings Guidance for the Year 2023MDxHealth SA revised earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million.
お知らせ • Oct 05MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023MDxHealth SA announced that they will report Q3, 2023 results at 5:40 PM, Central European Standard Time on Oct 09, 2023
お知らせ • Aug 24MDxHealth SA Reaffirms Revenue Guidance for the Year 2023MDxHealth SA announced that the company reaffirms full year 2023 revenue guidance of $65 million - $70 million.
お知らせ • Jan 10+ 1 more updateMDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023MDxHealth SA announced that they will report first half, 2023 results on Aug 23, 2023
